Ipol Side Effects

Generic name: poliovirus vaccine, inactivated

Medically reviewed by Drugs.com. Last updated on Jun 30, 2024.

Note: This document provides detailed information about Ipol Side Effects associated with poliovirus vaccine, inactivated. Some dosage forms listed on this page may not apply specifically to the brand name Ipol.

Applies to poliovirus vaccine, inactivated: injection suspension.

Serious side effects of Ipol

Along with its needed effects, poliovirus vaccine, inactivated (the active ingredient contained in Ipol) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking poliovirus vaccine, inactivated:

Symptoms of allergic reaction

• difficulty with breathing or swallowing
• hives
• itching, especially of the feet or hands
• reddening of the skin, especially around ears
• swelling of the eyes, face, or inside of the nose
• unusual tiredness or weakness (sudden and severe)

More common side effects

• fever over 102° F (39° C)

Other side effects of Ipol

Some side effects of poliovirus vaccine, inactivated may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• irritability
• loss of appetite
• tiredness

Less common side effects

• itching or skin rash
• redness, soreness, hard lump, tenderness, or pain at the place of injection

For healthcare professionals

Applies to poliovirus vaccine, inactivated: injectable suspension.

Local adverse events

• Very common (10% or more): Injection site pain (34%), local tenderness (29.4%), local swelling (11.4%)
• Common (1% to 10%): Local erythema
• Uncommon (0.1% to 1%): Injection site mass
• Postmarketing reports: Injection site reaction (including injection site rash)^[Ref]

Other

• Very common (10% or more): Temperature over 102F (38%)
• Common (1% to 10%): Persistent crying
• Frequency not reported: Death
• Postmarketing reports: Pyrexia^[Ref]

Psychiatric

• Very common (10% or more): Irritability (64.5%), tiredness (60.7%) fussiness, sleepiness
• Postmarketing reports: Agitation^[Ref]

Metabolic

• Very common (10% or more): Anorexia (16.6%)^[Ref]

Gastrointestinal

• Common (1% to 10%): Vomiting, diarrhea^[Ref]

Nervous system

• Frequency not reported: Guillain-Barre syndrome
• Postmarketing reports: Convulsion, febrile convulsion, headache, paresthesia^[Ref]

Hypersensitivity

• Postmarketing reports: Type I hypersensitivity reaction (including allergic reaction, anaphylactic reaction, and anaphylactic shock)^[Ref]

Musculoskeletal

• Postmarketing reports: Arthralgia, myalgia^[Ref]

Hematologic

• Postmarketing reports: Lymphadenopathy^[Ref]

Dermatologic

• Postmarketing reports: Rash, urticaria^[Ref]

Further information

Ipol side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer